BURLINGTON, Mass., Aug. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the asthma market in Brazil and Mexico currently faces severe coverage restrictions. The uptake of several newly approved agents, the anticipated label extension of Boehringer Ingelheim/Pfizer's Spiriva for this indication and the launch of emerging biologics will substantially increase the competitiveness of these asthma markets. In particular, the emerging IL-5 inhibitors will introduce a new dynamic to the severe, disease-refractory market segment. In terms of patients for whom Genentech/Novartis's Xolair (omalizumab) is currently the only therapeutic option, the severe, disease-refractory market segment is characterized by high morbidity and frequent hospitalizations. Additionally, the treatment of severe, refractory asthma is a burden to the healthcare systems in Brazil and Mexico, and reducing direct costs such as those associated with acute exacerbations and the need for hospitalization and ER visits is one of the most valuable attributes for formulary inclusion.
Other key findings from the Emerging Markets Physician and Payer Forum report entitled Positioning of Current and Emerging Agents for Asthma: Physician and Payer Perspectives on the Prescribing and Patient Access Landscape in Brazil and Mexico include:
Comments from Decision Resources Group Director Andreia Ribeiro, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
|SOURCE Decision Resources Group|
Copyright©2014 PR Newswire.
All rights reserved